Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects

The effect of the protease‐activated receptor‐1 (PAR‐1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two‐period, open‐label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady‐s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraft, WK, Gilmartin, JH, Chappell, DL, Gheyas, F, Walker, BM, Nagalla, S, Naik, UP, Horrow, JC, Wrishko, RE, Zhang, S, Anderson, MS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351335/
https://www.ncbi.nlm.nih.gov/pubmed/27304196
http://dx.doi.org/10.1111/cts.12405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351335/
https://www.ncbi.nlm.nih.gov/pubmed/27304196
http://dx.doi.org/10.1111/cts.12405

Ejemplares similares